BHPI

BHPI is an antagonist of estrogen receptor alpha (ERalpha) that blocks 17beta-estradiol-induced proliferation of drug-resistant breast, endometrial, and ovarian cancer cell lines at concentrations ranging from 10 to 1,000 nM. It is effective in vivo, driving tumor regression in mice bearing MCF-7 xenografts at a dose of 15 mg/kg daily. BHPI specifically inhibits ERalpha-dependent gene expression and protein synthesis by activating the unfolded protein response in cells.Formal Name: 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-methyl-2H-indol-2-one. CAS Number: 56632-39-4. Molecular Formula: C21H17NO3. Formula Weight: 331.4. Purity: >95%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 5 mg/ml, DMSO: 11 mg/ml, Ethanol: 14 mg/ml, Ethanol:PBS(pH 7.2) (1:1): 0.5 mg/ml. SMILES: CC1=C(NC(C2(C3=CC=C(O)C=C3)C4=CC=C(O)C=C4)=O)C2=CC=C1. InChi Code: InChI=1S/C21H17NO3/c1-13-3-2-4-18-19(13)22-20(25)21(18,14-5-9-16(23)10-6-14)15-7-11-17(24)12-8-15/h2-12,23-24H,1H3,(H,22,25). InChi Key: FABLAHMQSQFDHR-UHFFFAOYSA-N.